Clinical utility of circulating tumor cells in ALK-positive non-small-cell lung cancer

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Faugeroux, Vincent ^a,b   Pailler, Emma ^a,b   Auger, Nathalie ^b   Taylor, Melissa ^a,b   Farace, Françoise ^a,b  

^a Universite Paris Sud   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

ALK rearrangement; Circulating tumor cells; Non small cell lung cancer; Predictive biomarker; Targeted therapy

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84928349617     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00281     Document Type: Article

References (17)

1. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol (2014) 232(2):121-33. doi:10.1002/path.4275
2. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 101(36):13306-11. doi:10.1073/pnas.0405220101
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-500. doi:10.1126/science.1099314
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350(21):2129-39. doi:10.1056/NEJMoa040938
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 13(3):239-46. doi:10.1016/S1470-2045(11)70393-X
6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 363(18):1693-703. doi:10.1056/NEJMoa1006448
7. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448(7153):561-6. doi:10.1038/nature05945
8. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol (2009) 27(26):4232-5. doi:10.1200/JCO.2009.23.6661
9. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 16(22):5581-90. doi:10.1158/1078-0432.CCR-10-0851
10. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 13(10):1011-9. doi:10.1016/S1470-2045(12)70344-3
11. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 368(25):2385-94. doi:10.1056/NEJMoa1214886
12. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 370(26):2537-9. doi:10.1056/NEJMc1404894
13. Wang J, Cai Y, Dong Y, Nong J, Zhou L, Liu G, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS One (2014) 9(7):e101551. doi:10.1371/journal.pone.0101551
14. Mostert B, Sleijfer S, Foekens JA, Gratama JW. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev (2009) 35(5):463-74. doi:10.1016/j.ctrv.2009.03.004
15. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer (2011) 105(9):1338-41. doi:10.1038/bjc.2011.405
16. Ilie M, Long E, Butori C, Hofman V, Coelle C, Mauro V, et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol (2012) 23(11):2907-13. doi:10.1093/annonc/mds137
17. Pailler E, Adam J, Barthelemy A, Oulhen M, Auger N, Valent A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol (2013) 31(18):2273-81. doi:10.1200/JCO.2012.44.5932